1. Home
  2. IGC vs MKTW Comparison

IGC vs MKTW Comparison

Compare IGC & MKTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGC
  • MKTW
  • Stock Information
  • Founded
  • IGC 2005
  • MKTW 1999
  • Country
  • IGC United States
  • MKTW United States
  • Employees
  • IGC N/A
  • MKTW N/A
  • Industry
  • IGC Biotechnology: Pharmaceutical Preparations
  • MKTW Computer Software: Prepackaged Software
  • Sector
  • IGC Health Care
  • MKTW Technology
  • Exchange
  • IGC Nasdaq
  • MKTW Nasdaq
  • Market Cap
  • IGC 26.9M
  • MKTW 23.1M
  • IPO Year
  • IGC N/A
  • MKTW N/A
  • Fundamental
  • Price
  • IGC $0.35
  • MKTW $0.56
  • Analyst Decision
  • IGC Strong Buy
  • MKTW Buy
  • Analyst Count
  • IGC 2
  • MKTW 2
  • Target Price
  • IGC $3.63
  • MKTW $2.50
  • AVG Volume (30 Days)
  • IGC 222.5K
  • MKTW 549.4K
  • Earning Date
  • IGC 11-12-2024
  • MKTW 11-07-2024
  • Dividend Yield
  • IGC N/A
  • MKTW 7.33%
  • EPS Growth
  • IGC N/A
  • MKTW N/A
  • EPS
  • IGC N/A
  • MKTW 0.13
  • Revenue
  • IGC $1,183,000.00
  • MKTW $423,378,000.00
  • Revenue This Year
  • IGC N/A
  • MKTW N/A
  • Revenue Next Year
  • IGC $13.57
  • MKTW N/A
  • P/E Ratio
  • IGC N/A
  • MKTW $4.09
  • Revenue Growth
  • IGC N/A
  • MKTW N/A
  • 52 Week Low
  • IGC $0.25
  • MKTW $0.47
  • 52 Week High
  • IGC $0.91
  • MKTW $3.50
  • Technical
  • Relative Strength Index (RSI)
  • IGC 42.76
  • MKTW 47.35
  • Support Level
  • IGC $0.33
  • MKTW $0.49
  • Resistance Level
  • IGC $0.42
  • MKTW $0.56
  • Average True Range (ATR)
  • IGC 0.02
  • MKTW 0.05
  • MACD
  • IGC -0.00
  • MKTW 0.00
  • Stochastic Oscillator
  • IGC 32.14
  • MKTW 39.06

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

About MKTW MarketWise Inc.

Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.

Share on Social Networks: